Pharmaceutical

Biogen's strong quarter eclipsed by patient death

Biogen's strong quarter eclipsed by patient death

Despite strong performance by its MS therapies, the drugmaker's robust third-quarter sales were overshadowed by the death of a patient taking Tecfidera.The patient had a rare brain infection.

GSK restructures, as respiratory disappoints

GSK restructures, as respiratory disappoints

GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.

NIH tests second Ebola vax in humans

Canada's National Microbiology Laboratory developed the vaccine, which has been licensed to NewLink Genetics Corp.

Actavis, Sanofi reportedly spar for Omega

Bloomberg reports that the race to merge with Omega also includes privately-held Boehringer Ingelheim and Perrigo.

Senate hearing may be on horizon for HCV drug prices

Sen. Bernard Sanders (I-VT) could hold a hearing after midterm elections to discuss the impact of costly new HCV treatments on the US Department of Veterans' Affairs.

Study hints at how brands should reach Millennials

Study hints at how brands should reach Millennials

The Post X-er, Post-Boomer generation considers traditional healthcare "sick care."

Five things for pharma marketers to know: Tuesday, October 21

Five things for pharma marketers to know: Tuesday, October 21

Shire bows out of AbbVie acquisition; CVS's PBM will charge premium for consumers who fill scripts at tobacco-selling pharmacies; Reckitt Beckinser will rebrand following demerger.

Crohn's drug shows promise in mid-stage trial

Crohn's drug shows promise in mid-stage trial

Preliminary Phase-II data suggest remission rates among patients taking the drug were significantly better than those for subjects on current treatments.

Takeda's Contrave hits pharmacy shelves

Takeda's Contrave hits pharmacy shelves

Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.

Valeant-Allergan duel continues

Valeant indicated in its third-quarter earnings call that it expects to increase its bid for Allergan.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.